Dr. Shore on extended follow-up data for darolutamide in nonmetastatic CRPC

Laura Bukavina, MD, MPH, highlights a BCAN Think Tank session on real-world applications of microbiome in bladder cancer.

Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.

Suzanne Merrill, MD, recaps the BCAN 2023 Think Tank session she co-chaired that covered prehabilitation programs, urinary diversion management, and other focal areas aimed at enhancing the quality of bladder cancer care in the community.

Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 AUA meeting.

"I'm really optimistic that the session we are conducting will provide some recommendations [and] some ideas that will help us think about utilizing epigenetic therapies in a very evidence-based way," says Ania Woloszynska, PhD.

Treatment with the first-line combination of pembrolizumab and lenvatinib led to durable anti-tumor activity in patients with non–clear cell renal cell carcinoma.